EDITORIAL

Liver transplantation in HCV/HIV positive patients

Yasuhiko Sugawara, Sumihito Tamura, Norihiro Kokudo

Yasuhiko Sugawara, Sumihito Tamura, Norihiro Kokudo, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
Author contributions: Sugawara Y, Tamura S and Kokudo N wrote this editorial together.
Correspondence to: Yasuhiko Sugawara, MD, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. yasusuga-tky@umin.ac.jp
Telephone: +81-3-38155411   Fax: +81-3-56843989

Abstract

Since the introduction of highly active antiretroviral therapy (HAART) in 1996 for human immunodeficiency virus (HIV)-infected patients, the incidence of liver diseases secondary to co-infection with hepatitis C has increased. Although data on the outcome of liver transplantation in HIV-infected recipients is limited, the overall results to date seem to be comparable to that in non-HIV-infected recipients. Liver transplant centers are now accepting HIV-infected individuals as organ recipients. Post-transplantation HIV replication is controlled by HAART. Hepatitis C re-infection of the liver graft, however, remains an important problem because cirrhotic changes of the liver graft may be more rapid in HIV-infected recipients. Interactions between the HAART components and immunosuppressive drugs influence drug metabolism and therefore meticulous monitoring of drug blood level concentrations is required. The risk of opportunistic infection in HIV-positive transplant patients seems to be similar to that in HIV-negative transplant recipients.

INTRODUCTION

Liver transplantation is an established standard therapeutic option for end-stage liver disease (ESLD) with a 1 year survival rate exceeding 80%[1]. Before the introduction of highly active antiretroviral therapy (HAART) in 1996, the results of transplantation for patients with human immunodeficiency virus (HIV) were poor[2-5] and HIV was considered a contraindication in most centers[6-8]. The 3 year survival rates were around 45% and the most frequent cause of death was acquired immune deficiency syndrome (AIDS)[2-5].

Since the introduction of HAART, HIV-related morbidity and mortality have dramatically decreased from 20-30 to 1.5-2.5 per 100 person-years[9,10]. In the setting of the improved prognosis in the HIV-infected population, the focus has turned to the morbidity and mortality associated with hepatitis C (HCV) and ESLD[11-15]. As HAART has changed HIV infection to a chronic condition, transplant centers around the world are slowly becoming less reluctant to accept HIV-positive patients as transplant recipients for both medical and ethical reasons[16-19] and liver transplantation is now considered a possible therapeutic option for these patients. The aim of the present review is to explore the new indications for liver transplantation in HIV/HCV co-infected patients.

EPIDEMIOLOGY OF HIV AND HAART

An estimated 33 million persons are currently living with HIV infection worldwide, including 16 million women and 2 million children less than 15 years of age[20]. In 2008, 2 million adults and 0.4 million children were newly infected and 2 million died from HIV infection. HIV infection is transmitted *via* heterosexual contact, intravenous drug use and homosexual contact.

Liver-related diseases among HIV-infected persons are caused by hepatitis B virus and/or HCV co-infection, hepatotoxic medication, alcohol and illegal drug use. Of these, co-infection with HCV is the most frequent cause of liver disease in HIV patients and substantially contributes to morbidity and mortality[21,22]. HIV and HCV usually share common routes of transmission. Approximately 4 to 5 million HIV-infected persons are co-infected with HCV. The prevalence of co-infection differs by geographical region and by patient demographical and behavioral characteristics ranging from 1%-5% in persons who acquired HIV infection by heterosexual or homosexual contact to 70%-95% in patients with current or former injecting drug use and transfused hemophiliac patients[23].

HCV MANAGEMENT BEFORE TRANSPLANTATION

There are several challenges in the management of HIV/HCV co-infected patients who require transplantation. The first is to minimize mortality while on the organ transplant waiting list because such patients frequently have a more rapid progression from the first decompensation to death. The interval between the first manifestation of liver decompensation and death is 16 mo for HIV/HVC co-infected versus 48 mo for HIV mono-infected patients. Prognostic factors after first decompensation include age, severity of liver disease [model for end-stage liver disease (MELD) score] and the nature of the decompensation event[24].

HCV/HIV co-infections adversely affect each other: HIV infection accelerates the progression of HCV disease by increasing HCV viremia, causing cellular immunodeficiency, increasing the risk of liver fibrosis and cirrhosis and leading to the rare fibrosing cholestatic hepatitis[25,26]. HCV may adversely affect the course of HIV infection[27,28] by reducing the efficacy of antiretroviral treatment and increasing the rate of antiretroviral medication-related hepatotoxicity[25,29]. The effect of antiretroviral therapy to reduce liver-related mortality in HCV co-infected persons is controversial[10,30]. Some co-infected persons are not eligible for HCV treatment due to somatic or psychosocial comorbidities, contraindications for HCV drugs and decompensated cirrhosis[31].

INDICATIONS FOR TRANSPLANTATION

Table 1 showed the inclusion criteria for liver transplantation. The acceptance criteria for liver transplanta-tion in HIV-positive recipients continue to evolve with increased experience with the co-infected population. In deceased donor liver transplantation, there are ethical concerns regarding the use of a scarce resource for a group of recipients with unknown survival duration. The acceptance criteria have gradually expanded, however, based on acceptable initial results[32-34].

The best timing for liver transplantation from the point of view of liver damage (Child-Pugh or MELD) is unknown. Pre-transplant survival for liver candidates is reported to be poorer in HIV-infected individuals compared with others awaiting liver transplantation, despite equivalent MELD scores[24,35]. In one study, significantly fewer HIV patients (26% of 58) survived on a liver transplant waiting list compared to candidates without HIV (63% of 860)[36]. Although more rapid deterioration in HIV co-infected patients may be the cause[37], death in that study was not associated with MELD, viral load, CD4, ability to tolerate medications or HCV progression. Further studies are necessary to understand the risk factors for death in HIV-positive patients on the liver transplant waiting list[38].

The inclusion criteria of an NIH sponsored study in the USA[39] are AIDS-related opportunistic infections or cancers that are resolved by sufficient treatment prior to transplant. CD4 counts should be greater than 100/mL for those without a history of opportunistic infection and greater than 200/mL for those with a history of opportunistic infection completely treated before transplantation. These requirements may be applied 3 to 4 mo prior to transplantation. Opportunistic infections include chronic cryptosporidiosis, progressive multifocal leukoencephalopathy and multi-drug resistant systemic fungal infections. Patients with a history of AIDS-associated lymphoma should be excluded. Most clinical trials include individuals with a history of resolved cutaneous Kaposi's sarcoma if a recent high-resolution computed tomography scan reveals no evidence of pulmonary lesions[40].

In a Spanish consensus statement[41], the criteria are similar except for the requirement of CD4 cell counts greater than 350/mL in patients that do not fulfill the HAART criteria. Ragni *et al*[32] noted that cumulative survival among HIV-positive recipients is similar to that of age- and race-comparable HIV-negative recipients.

Another potential conflict regarding the absolute requirement for a CD4 cell count greater than 100/mL relates to the use of interferon therapy[42]. In a recent series at Paul Brousse Hospital[42], CD4 cell counts greater than 150/mL were observed in 7 patients and 6 of these 7 patients developed severe chronic HCV. The use of interferon can cause a transient decrease in CD4 cell counts. The absolute CD4 cell count prior to interferon therapy should be taken into account in the decision regarding liver transplantation.

HIV-RNA should be undetectable at transplantation. Unfortunately, however, most recipients cannot tolerate HAART therapy due to its hepatotoxicity. When an undetectable HIV viral load is not achievable, an experienced HIV clinician should predict the ability to

Table 1 Inclusion criteria for liver transplantation	
NIH sponsored study in the USA[94]	1. No AIDS-related opportunistic infections
	2. CD4 counts should be > 100/mL for those without a history of opportunistic infection and > 200/mL for those with a history of opportunistic infection.
	3. HIV-RNA should be undetectable. In the event that an undetectable HIV viral load is not achievable as a result of drug-induced hepatotoxic, an HIV clinician should predict the ability to control the HIV virus post-transplantation.
Spanish criteria[41]	1. No opportunistic infections
	2. CD4 counts > 100/mL
	3. HIV-RNA should be undetectable or suppressible with antiretroviral therapy.
O'Grady[95]	1. Absence of AIDS-defining illness after immune reconstitution
	2. CD4 counts should be > 200/mL or > 100/mL in the presence of portal hypertension.
	3. Absence of HIV viremia
	4. Antiretroviral therapeutic options available if the HIV disease reactivates

AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus.

control HIV after the transplantation, based on a complete review of the antiretroviral history, HIV RNA history and resistance testing[43]. This issue is more controversial for patients with CD4 counts greater than 100/mL but who have detectable HIV that is multi-drug-resistant. Currently, most centers still consider this an exclusion criterion, although with more data demonstrating the safety of immunosuppression in the HIV-positive patient as well as an increasing number of antiretroviral agents, this exclusion criterion may be liberalized on a case by case basis[44].

SURGICAL RESULTS

Survival

Survival at 1 year post-transplantation ranges from 58% to 89% (Table 2). Ragni et al[32] reported 1, 2 and 3 year survival rates of 87%, 73% and 73% in 24 HIV-positive patients which were not statistically different from age and race-matched HIV-negative patients. Similar results[45] were reported based on an analysis of 15 HIV-positive recipients with a 3 year survival rate of 73% compared to 79% for HIV-negative recipients. Neff et al[33] reported that graft and patient survival rates in HIV-positive patients are similar to that of HIV-negative patients transplanted for the same indication. Studies that analyzed liver transplantation for a variety of reasons showed excellent outcome for ESLD irrespective of underlying HIV infection. Another report showed lower survival rates in 27 patients with 1, 3 and 5 year survival rates of 67%, 56% and 33% respectively[35]. A Spanish series found HIV-positive patient survival rates of 90% at 1 year and 67% at 3 years[46].

Two recently published studies comparing survival in HCV/HIV-co-infected and HCV-mono-infected transplant recipients reported a significantly lower survival rate in co-infected patients[35,42]. In a French study of 35 HCV/HIV-infected and 44 HCV-infected recipients, 2 and 5 year patient survival rates were statistically lower in co-infected patients, 73% vs 91% and 51% vs 81% respectively[42]. MELD was the only significant predictor for mortality and HIV infection did not predict survival. In a US study[35] of 27 HCV/HIV-infected and 41 HCV-infected recipients, the 3 and 5 year patient survival rates tended to

be lower in co-infected patients, 56% vs 72% and 33% vs 72% respectively.

In a review of the United Network for Organ Sharing liver transplant database (between 1997 and 2006)[47], the 2 and 3 year survival rates in 138 HIV-positive recipients were 70% and 66% respectively. These outcomes were slightly worse than the 2 and 3 year survival rates of 81% and 77% respectively of the 30 520 HIV-negative recipients (P < 0.05). The overall results of liver transplantation in HIV-positive patients are favorable but large prospective clinical trials providing insight into survival and clinical management are required.

Complications

Rejection episode rates in HIV-positive recipients are not different from those of HIV-negative recipients[42]. HIV-associated opportunistic infections and AIDS-related diseases are uncommon. Only a single case of Kaposi's sarcoma and multicentric Castleman's disease has been reported[48]. Death from infectious complications, however, is reported to be more frequent in HIV-positive recipients[45]. Importantly, no HIV disease progression has been reported and HIV replication is efficiently controlled by HAART[32,35,42,49,50]. An exception, though, is the report by Schreibman et al[45] that HIV-infected patients experienced significantly higher mortality from infectious complications (4 of 15 recipients). The results of HCC cases within Milan-criteria are encouraging and there are no reports of recurrences[33,35,45,48,49,51-54].

Prognostic factors

A recent report[42] identified high MELD scores at the time of transplant as predictive of a poor outcome. Early and severe HCV graft re-infection is a major determinant influencing post-transplant outcome[32,34,48,51-53,55-58]. Another report[35] showed that HAART intolerance is a significant predictor. Other risk factors include low pre-transplant body mass index and African American race[59].

POSTOPERATIVE MANAGEMENT

Immunosuppression and HAART

Cyclosporine (CyA) inhibits CD4 cell apoptosis and

Table 2 Survival, hepatitis C virus recurrence, and therapy in hepatitis C virus/human immunodeficiency virus co-infected liver transplant patients

References	Institution	Years	*n*	Genotypes	Time to recurrence (mo)	IFN and RBV doses	Time to therapy (mo)	SVR (%)	FCH (*n*)	Death (*n*)	Follow up (mo)
Prachialis 2001[58], Norris 2004[56]	King's College	95-03	7	NA	5	From 2 wk: IFN, 3 MU tiw and RBV, after 3 wk: Peg- IFN 180 µg/wk	0.5 (*n* = 2), 6 m (*n* = 1)	0	2	5	12
Rafecas 2004[51]	Hospital Universitari de Bellvitge	02-03	4	4, 1b, 1b, 1a	7	NA	5 (*n* = 3)	0	0	0	17
Moreno 2005[55]	Hospital Ramon (Madrid)	02-03	4	NA	1-6	NA	1-6	0	1	1	14-18
Radecke 2005[57]	University Hospital Essen	98-01	4	NA	3-8	NA	NA	NA	1	2	10-61
Vogel 2005[48]	Bonn University	97-04	4	1a (*n* = 2), 2a/2c, 3a	1-8	NA	5-15	50	0	0	NA
Neff 2003[33], Fung 2004[71], de Vera 2006[35]	Thomas E Starzl Transplantation Institute	97-05	27	1 (*n* = 16), 2 (*n* = 2), 3 (*n* = 1)	6	IFN and Peg -IFN, RBV 800 mg/d	2-50	27	6	14	27+-5
Castells 2007[53]	Hospital Universitari Vall d'Hebro'n (Barcelona)	02-05	9	1 (*n* = 7), 3 (*n* = 2)	3+-3	Peg-IFN 1.5 µg/kg, RBV 800-1000 mg/d	NA	14	0	1	15+-13
Schreibman 2007[45]	University of Miami	99-06	8	NA	NA	NA	NA	25	0	2	6-74
Vennarecci 2007[52]	Regina Elena Cancer Institute (Rome)	02-06	10	NA	NA	NA	NA	10	3	6	5-46
Wojcik 2007[88]	Medical University of Lodz (Poland)	97-06	4	1a (*n* = 2), 2a, 3a	1-3	Peg-IFN 180 µg/wk, RBV 200-1000 mg/d	1-3	100	0	0	21-54
Duclos-Vallee 2005[50], 2008[42]	Paul Brousse	99-05	35	1 (*n* = 20), 2 (*n* = 1), 3 (*n* = 9), 4 (*n* = 4)	0-3	Peg-IFN 50-180 µg/wk, and RBV 400-800 mg/d	0-3	16	3	13	44+-83
Stock 2003[43], Roland 2008[96]	University of California, San Francisco	00-03	6	NA	1-11	NA	1-11	NA	2	4	NA
Testillano 2009[97]	Hospital de Cruces (Vizcaya)	01-07	12	1 (*n* = 8), 3 (*n* = 4)	NA	NA	NA	50	2	4	NA
Hughes 2010[98]	Emory University School of Medicine	NA	5	1	2-12	Peg-IFN 135-180 µg/wk, and RBV 600 mg/d	2-12	40	2	2	6-48
Di Benedetto 2008[54], 2010[99]	University of Modena and Reggio Emilia	03-	13	1 (*n* = 3), 3a (*n* = 7), 4 (*n* = 3)	2-16	Peg-IFN 50-180 µg/wk, and RBV 400-800 mg/d	NA	0	2	4	1-14

HCV: hepatitis C; IFN: interferon; Peg-IFN: pegylated interferon; RBV: ribavirin; SVR: sustained virological response; NA: not available; FCH: fibrosing cholestatic hepatitis.

p55Gag processing by binding to cyclophilin A[60-62]. Some beneficial effects of the combination of HAART and CyA have been demonstrated [63] but low-dose CyA exhibits no benefits in patients with stable early HIV disease[64].

Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase and depletes the pool of deoxyguanosine triphosphate. MMF is expected to reduce HIV infection by both virological and immunological mechanisms[65-70]. Antagonism due to the inhibition of thymidine kinase has been reported with MMF plus the thymidine analogues zidovudine and stavudine. Mitochondrial toxicity of nucleoside reverse transcriptase inhibitors (NRTI) is potentially augmented by the effect of MMF. Mitochondrial toxicity and lactic acidosis are linked to the use of didanosine, stavudine and zalcitabine and are attributed to damage to mitochondrial polymerase[71].

Sirolimus (SRL) downregulates the expression of chemokine receptor 5 on T-cells which is required for the propagation of macrophage tropic strains of HIV-1[72]. SRL inhibits the progression of Kaposi's sarcoma and primary effusion lymphoma[40,73].

Interactions between HAART drugs [protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs)] and calcineurin inhibitors or SRL are well described[74,75]. NNRTIs induce the expression of cytochrome P450, family A gene (CYP3A)[74]. PIs inhibit the production of cytochrome P450 enzymes or P-glycoprotein. CyA, tacrolimus and SRL are substrates of CYP3A4 and P-glycoprotein. PIs, therefore, increase

blood levels of CyA, tacrolimus and SRL, requiring dose reductions of 85 % to 99%[74-78] (Table 2). HAART without PIs may have fewer significant interactions with CyA, tacrolimus and SRL[79].

Efavirenz (NNRTI) induces the production cytochrome P450 enzymes[74] but when efavirenz or a nucleoside analogue combination are added to the treatment regimen, little change in the dosing of tacrolimus is required. In contrast, nelfinavir and lopinavir/ritonavir inhibit the first pass metabolism of tacrolimus, resulting in an increase in its elimination half-life and a reduction in its oral clearance[75].

Monitoring for HAART-associated hepatotoxicity is important. The use of NRTIs is associated with hepatic steatosis, mitochondrial dyfunction and fulminant hepatic failure[80,81]. PI-related hepatitis occurs in 5 % to 9% of patients[82] and has an aggressive course in HCV-positive patients[83]. Liver dysfunction is observed in up to 30% of patients taking NNRTIs[84]. A French study[50] reported evidence of mitochondrial dysfunction in 5 patients with severe recurrent HCV, with most patients developing mitochondrial dysfunction while on stavudine or stavudine plus didanosine and in patients concurrently using ribavirin.

To maintain virological control of HIV infection, quantitative HIV RNA and CD4 cell counts should be measured with the first assays at 1 mo after transplant and subsequent studies every 2 to 3 mo thereafter. If patients have persistent HIV viremia, resistance testing should be performed to determine treatment options[59].

HCV management
HCV recurrence is a significant problem following transplantation[35,42,50] although there are reports of spontaneous clearance of HCV post-transplantation[85]. HCV recurrence appears earlier in HIV-infected HCV patients than in HIV-uninfected HCV patients (median time 2 mo) and the rate of the progression of fibrosis is enhanced. In one controlled study, the proportion of patients with bridging fibrosis or cirrhosis at 2 and 5 years post-transplantation was 28% and 48% respectively for HCV-HIV co-infected patients versus 10% and 18% respectively in HCV-mono-infected patients[42]. HCV recurrence is attributed to graft loss (Table 2). The prognosis for patients with fibrosing cholestatic hepatitis is poor[42,53].

Pegylated interferon and ribavirin combination therapy is the mainstay for the management of recurrent HCV disease. The mitochondrial toxicity of HAART, however, increases when used in conjunction with ribavirin[86,87]. The rates of a sustained virological response (SVR) are low in co-infected patients, apart from one recent study that showed 100% SVR[88]. SVR occurs in only 11% to 27% of treated patients[35,42,88,89] (Table 2). Biochemical responses are obtained in more than half of patients but histological stabilization or improvement is rare in virological non-responders. Tolerability of the full dose therapy is limited, contributing to the poor SVR rates.

In the HCV-mono-infected population, viral factors (a high viral load before and after transplantation) and host factors (donor age > 50 years) are associated with a more severe recurrence of HCV[90]. Corticosteroid boluses are also associated with a severe HCV recurrence and should be avoided. Rapid corticosteroid withdrawal after transplantation should be avoided and may be associated with a more rapid progression of fibrosis[91]. The effects of immunosuppressant agents, including tacrolimus, CyA, MMF, anti-interleukin 2 receptor antibodies, SRL and azathioprine, on the severity of HCV recurrence are controversial[90].

Prophylaxis for opportunistic infections[59]
The risk of opportunistic infection in HIV-positive transplant patients seems to be similar to that of HIV-negative transplants. The ability to suppress HIV viral loads in patients on HAART is associated with the stabilization of, or improvement in, CD4 counts, which decreases opportunistic infection in HIV-positive patients[92].

Prophylactic regimens for preventing opportunistic infection include those against *Pneumocystis jirovecii* with trimethoprim-sulfamethoxazole, toxoplasmosis (for CD4 counts < 100), Mycobacterium avium complex (for CD4 counts < 50) and histoplasmosis and coccidioidomycosis. For patients at risk for primary toxoplasmosis due to donor infection, trimethoprim-sulfamethoxazole should be considered for primary prevention; dapsone or atovaquone in combination with pyrimethamine can be considered for patients intolerant to trimethoprim-sulfamethoxazole[71].

CONCLUSION
Clinical trials[35,41,48,56,71,88] suggest that liver transplantation in HIV/HCV co-infected patients is safe and that HIV infection does not influence the outcome. The United Network for Organ Sharing no longer considers HIV an absolute contraindication for transplantation. The French agency for Organ Distribution[93] has also concluded that there is no reason to consider HIV a contraindication. Spain has published a national policy[41] advocating liver transplantation for patients with HIV infection within defined criteria.

To improve the results of liver transplantation in HIV-infected individuals, better selection of candidates at an earlier stage of liver disease and optimization of donor and perioperative factors are needed. The natural history of HCV re-infection and treatment algorithms must also be determined as HCV recurrence is the most important concern. Better management of HAART after transplantation is also required.

REFERENCES
1   **Adam R**, Lucidi V, Karam V. Liver transplantation in Europe: is there a room for improvement? *J Hepatol* 2005; **42**: 33-40
2   **Gordon FH**, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. *Gut* 1998; **42**: 744-749
3   **Bouscarat F**, Samuel D, Simon F, Debat P, Bismuth H, Saimot

AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. *Clin Infect Dis* 1994; **19**: 854-859

4   **Erice A**, Rhame FS, Heussner RC, Dunn DL, Balfour HH, Jr. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. *Rev Infect Dis* 1991; **13**: 537-547

5   **Tzakis AG**, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV+ patients. *Transplantation* 1990; **49**: 354-358

6   **Spital A**. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. *Transplantation* 1998; **65**: 1187-1191

7   **Rubin RH**, Tolkoff-Rubin NE. The problem of human immunodeficiency virus (HIV) infection and transplantation. *Transpl Int* 1988; **1**: 36-42

8   **Mullen MA**, Kohut N, Sam M, Blendis L, Singer PA. Access to adult liver transplantation in Canada: a survey and ethical analysis. *CMAJ* 1996; **154**: 337-342

9   **Palella FJ Jr**, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998; **338**: 853-860

10   **Weber R**, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. *Arch Intern Med* 2006; **166**: 1632-1641

11   **Rosenthal E**, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, Michelet C, Pol S, Perronne C, Cacoub P. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). *J Viral Hepat* 2007; **14**: 183-188

12   **Bica I**, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. *Clin Infect Dis* 2001; **32**: 492-497

13   **Thio CL**, Seaberg EC, Skolasky R, Jr., Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet* 2002; **360**: 1921-1926

14   **Darby SC**, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. *Lancet* 1997; **350**: 1425-1431

15   **Colin JF**, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. *Hepatology* 1999; **29**: 1306-1310

16   **Halpern SD**, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. *N Engl J Med* 2002; **347**: 284-287

17   **Halpern SD**, Asch DA, Shaked A, Stock PG, Blumberg E. Determinants of transplant surgeons' willingness to provide organs to patients infected with HBV, HCV or HIV. *Am J Transplant* 2005; **5**: 1319-1325

18   **Roland ME**, Lo B, Braff J, Stock PG. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. *Arch Intern Med* 2003; **163**: 1773-1778

19   **Roland ME**, Havlir DV. Responding to organ failure in HIV-infected patients. *N Engl J Med* 2003; **348**: 2279-2281

20   UNAIDS/WHO. Global summary of HIV/AIDS epidemic, December 2008 Available from: URL: http://www.who. int/hiv/data/2009_global_summary.gif assessed August 27, 2010

21   **Alter MJ**. Epidemiology of viral hepatitis and HIV co-infection. *J Hepatol* 2006; **44**: S6-S9

22   **Koziel MJ**, Peters MG. Viral hepatitis in HIV infection. *N Engl J Med* 2007; **356**: 1445-1454

23   **Ragni MV**, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. *J Infect Dis* 2001; **183**: 1112-1115

24   **Polard E**, Camus C, Abault AY, Turlin B, Arvieux C, Messner M, Allain H, Boudjema K. Retransplantation for acute liver failure due to combined antiviral agents in an HIV-HCV coinfected liver transplant recipient. *Transplantation* 2005; **80**: 1136-1138

25   **Vallet-Pichard A**, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. *J Hepatol* 2006; **44**: S28-S34

26   **Alberti A**, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. *J Hepatol* 2005; **42**: 615-624

27   **Rockstroh JK**, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J Infect Dis* 2005; **192**: 992-1002

28   **Greub G**, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, Burgisser P, Erb P, Boggian K, Piffaretti JC, Hirschel B, Janin P, Francioli P, Flepp M, Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet* 2000; **356**: 1800-1805

29   **den Brinker M**, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. *AIDS* 2000; **14**: 2895-2902

30   **Qurishi N**, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. *Lancet* 2003; **362**: 1708-1713

31   **Zinkernagel AS**, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, Hirschel B, Tarr PE, Opravil M, Bernasconi E, Schmid P, Weber R. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. *Antivir Ther* 2006; **11**: 131-142

32   **Ragni MV**, Belle SH, Im K, Neff G, Roland M, Stock P, Heaton N, Humar A, Fung JF. Survival of human immunodeficiency virus-infected liver transplant recipients. *J Infect Dis* 2003; 188: 1412-1420

33   **Neff GW**, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, Shakil O, Fung JJ. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. *Liver Transpl* 2003; **9**: 239-247

34   **Stock PG**, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, Terrault NA, Frassetto LA, Palefsky JM, Tomlanovich SJ, Ascher NL. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. *Transplantation* 2003; **76**: 370-375

35   **de Vera ME**, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, Marcos A, Demetris A, Jain A, Fung JJ, Ragni MV. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. *Am J Transplant* 2006; **6**: 2983-2993

36   **Ragni MV**, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ.

Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. *Liver Transpl* 2005; **11**: 1425-1430

37 **Pineda JA**, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, Andrade RJ, Gonzalez-Serrano M, Aguilar J, Aguilar-Guisado M, Navarro JM, Salmeron J, Caballero-Granado FJ, Garcia-Garcia JA. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. *Hepatology* 2005; **41**: 779-789

38 **Huprikar S**. Solid organ transplantation in HIV-infected individuals: an update. *Rev Med Virol* 2009; **19**: 317-323

39 **Roland ME**, Stock PG. Liver transplantation in HIV-infected recipients. *Semin Liver Dis* 2006; **26**: 273-284

40 **Stallone G**, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. *N Engl J Med* 2005; **352**: 1317-1323

41 **Miro JM**, Torre-Cisnero J, Moreno A, Tuset M, Quereda C, Laguno M, Vidal E, Rivero A, Gonzalez J, Lumbreras C, Iribarren JA, Fortun J, Rimola A, Rafecas A, Barril G, Crespo M, Colom J, Vilardell J, Salvador JA, Polo R, Garrido G, Chamorro L, Miranda B. [GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. *Enferm Infecc Microbiol Clin* 2005; **23**: 353-362

42 **Duclos-Vallee JC**, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, Azoulay D, Adam R, Bismuth H, Castaing D, Vittecoq D, Samuel D. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. *Hepatology* 2008; **47**: 407-417

43 **Roland ME**, Stock PG. [Comprehensive guidelines translate research findings into clinical policy for HIV-infected transplant candidates and recipients.]. *Enferm Infecc Microbiol Clin* 2005; **23**: 331-334

44 **Samuel D**, Weber R, Stock P, Duclos-Vallee JC, Terrault N. Are HIV-infected patients candidates for liver transplantation? *J Hepatol* 2008; **48**: 697-707

45 **Schreibman I**, Gaynor JJ, Jayaweera D, Pyrsopoulos N, Weppler D, Tzakis A, Schiff ER, Regev A. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. *Transplantation* 2007; **84**: 697-705

46 **Miro J**, Montejo M, Castells L, Rafecas A, Salcedo M, Fortu'n J. Prognostic Factors of Mortality in HCV/HIV Coinfected Liver Transplant Recipients From the FIPSE OLT-HIV-05-GESIDA 45-05 Cohort Study (2002-2006). 15th CROI Meeting, Boston, MA, 2008: 177

47 **Mindikoglu AL**, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. *Transplantation* 2008; **85**: 359-368

48 **Vogel M**, Voigt E, Schafer N, Goldmann G, Schwarz N, Kalff JC, Sauerbruch T, Wolff M, Rockstroh JK, Spengler U. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. *Liver Transpl* 2005; **11**: 1515-1521

49 **Terrault NA**, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. *Liver Transpl* 2006; **12**: 801-807

50 **Duclos-Vallee JC**, Vittecoq D, Teicher E, Feray C, Roque-Afonso AM, Lombes A, Jardel C, Gigou M, Dussaix E, Sebagh M, Guettier C, Azoulay D, Adam R, Ichai P, Saliba F, Roche B, Castaing D, Bismuth H, Samuel D. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. *J Hepatol* 2005; **42**: 341-349

51 **Rafecas A**, Rufi G, Figueras J, Fabregat J, Xiol X, Ramos E, Torras J, Llado L, Serrano T. Liver transplantation without

steroid induction in HIV-infected patients. *Liver Transpl* 2004; **10**: 1320-1323

52 **Vennarecci G**, Ettorre GM, Antonini M, Santoro R, Perracchio L, Visco G, Santoro E. Liver transplantation in HIV-positive patients. *Transplant Proc* 2007; **39**: 1936-1938

53 **Castells L**, Escartin A, Bilbao I, Len O, Allende H, Vargas V, Ribera E, Lazaro JL, Bueno J, Balsells J, Esteban R, Pahissa A, Margarit C. Liver transplantation in HIV-HCV coinfected patients: a case-control study. *Transplantation* 2007; **83**: 354-358

54 **Di Benedetto F**, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, Ballarin R, Codeluppi M, Guaraldi G, Gerunda GE. Hepatocellular carcinoma in HIV patients treated by liver transplantation. *Eur J Surg Oncol* 2008; **34**: 422-427

55 **Moreno S**, Fortun J, Quereda C, Moreno A, Perez-Elias MJ, Martin-Davila P, de Vicente E, Barcena R, Quijano Y, Garcia M, Nuno J, Martinez A. Liver transplantation in HIV-infected recipients. *Liver Transpl* 2005; **11**: 76-81

56 **Norris S**, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, Rela M, Heaton N, O'Grady JG. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. *Liver Transpl* 2004; **10**: 1271-1278

57 **Radecke K**, Fruhauf NR, Miller M, Ross B, Koditz R, Malago M, Broelsch CE, Gerken G, Treichel U. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. *Liver Int* 2005; **25**: 101-108

58 **Prachalias AA**, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, Cramp M, Williams R, O'Grady J, Rela M, Heaton ND. Liver transplantation in adults coinfected with HIV. *Transplantation* 2001; **72**: 1684-1648

59 **Blumberg EA**, Stock P. Solid organ transplantation in the HIV-infected patient. *Am J Transplant* 2009; **9** Suppl 4: S131-S135

60 **Groux H**, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. *J Exp Med* 1992; **175**: 331-340

61 **Streblow DN**, Kitabwalla M, Malkovsky M, Pauza CD. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. *Virology* 1998; **245**: 197-202

62 **Bartz SR**, Hohenwalter E, Hu MK, Rich DH, Malkovsky M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. *Proc Natl Acad Sci USA* 1995; **92**: 5381-5385

63 **Rizzardi GP**, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Chave JP, Lazzarin A, Pantaleo G. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. *J Clin Invest* 2002; **109**: 681-688

64 **Calabrese LH**, Lederman MM, Spritzler J, Coombs RW, Fox L, Schock B, Yen-Lieberman B, Johnson R, Mildvan D, Parekh N. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. *J Acquir Immune Defic Syndr* 2002; **29**: 356-362

65 **Chapuis AG**, Paolo Rizzardi G, D'Agostino C, Attinger A, Knabenhans C, Fleury S, Acha-Orbea H, Pantaleo G. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. *Nat Med* 2000; **6**: 762-768

66 **Garcia F**, Plana M, Arnedo M, Brunet M, Castro P, Gil C, Vidal E, Millan O, Lopez A, Martorell J, Fumero E, Miro JM, Alcami J, Pumarola T, Gallart T, Gatell JM. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. *J Acquir Immune Defic Syndr* 2004; **36**: 823-830

67 **Hossain MM**, Coull JJ, Drusano GL, Margolis DM. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. *Antiviral Res* 2002; **55**: 41-52

68 **Margolis D**, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor

of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. *J Acquir Immune Defic Syndr* 1999; **21**: 362-370

69   **Heredia A**, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. *J Acquir Immune Defic Syndr* 1999; **22**: 406-407

70   **Coull JJ**, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. *J Acquir Immune Defic Syndr* 2001; **26**: 423-434

71   **Fung J**, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. *Liver Transpl* 2004; **10**: S39-S53

72   **Heredia A**, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. *Proc Natl Acad Sci USA* 2003; **100**: 10411-10416

73   **Sin SH**, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD, Henry D, Harrington WJ Jr., Damania BA, Dittmer DP. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. *Blood* 2007; **109**: 2165-2173

74   **Frassetto L**, Baluom M, Jacobsen W, Christians U, Roland ME, Stock PG, Carlson L, Benet LZ. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. *Transplantation* 2005; **80**: 13-17

75   **Teicher E**, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, Duclos-Vallee JC, Taburet AM, Samuel D, Vittecoq D. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. *Clin Pharmacokinet* 2007; **46**: 941-952

76   **Sheikh AM**, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. *Transplantation* 1999; **68**: 307-309

77   **Vogel M**, Voigt E, Michaelis HC, Sudhop T, Wolff M, Turler A, Sauerbruch T, Rockstroh JK, Spengler U. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. *Liver Transpl* 2004; **10**: 939-944

78   **Jain AK**, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, Pokharna R, Rohal S, Ragni M, Fung JJ. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. *Transplant Proc* 2002; **34**: 1540-1541

79   **Izzedine H**, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. *Kidney Int* 2004; **66**: 532-541

80   **Chariot P**, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, Schaeffer A, Zafrani ES. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. *J Hepatol* 1999; **30**: 156-160

81   **Lai KK**, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2', 3'-dideoxyinosine (ddI). *Ann Intern Med* 1991; **115**: 283-284

82   **Arribas JR**, Ibanez C, Ruiz-Antoran B, Pena JM, Esteban-Calvo C, Frias J, Vazquez JJ, Gonzalez-Garcia JJ. Acute hepatitis in HIV-infected patients during ritonavir treatment. *AIDS* 1998; **12**: 1722-1724

83   **Sulkowski MS**, Thomas DL, Chaisson RE, Moore RD. Elevated liver enzymes following initiation of antiretroviral therapy. *JAMA* 2000; **283**: 2526-2567

84   **Martinez E**, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A, Gatell JM. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. *AIDS* 2001; **15**: 1261-1268

85   **Bhagat V**, Foont JA, Schiff ER, Regev A. Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. *Liver Transpl* 2008; **14**: 92-95

86   **Lafeuillade A**, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. *Lancet* 2001; **357**: 280-281

87   **Antoniades C**, Macdonald C, Knisely A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. *Liver Transpl* 2004; **10**: 699-702

88   **Wojcik K**, Vogel M, Voigt E, Speidel N, Kalff JC, Goldmann G, Oldenburg J, Sauerbruch T, Rockstroh JK, Spengler U. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. *Aids* 2007; **21**: 1363-1365

89   **Castells L**, Esteban JI, Bilbao I, Vargas V, Allende H, Ribera E, Piron M, Sauleda S, Len O, Pahissa A, Esteban R, Guardia J, Margarit C. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. *Antivir Ther* 2006; **11**: 1061-1070

90   **Roche B**, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. *J Viral Hepat* 2007; **14** Suppl 1: 89-96

91   **Berenguer M**, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. *Liver Transpl* 2007; **13**: 21-29

92   **Price P**, Mathiot N, Krueger R, Stone S, Keane NM, French MA. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. *J Clin Virol* 2001; **22**: 279-287

93   **Samuel D**, Duclos Vallee JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. *J Hepatol* 2003; **39**: 3-6

94   Solid Organ Transplantation in HIV: Multi-Site Study Version 7.0, July 2009. Available from: URL: http://www.HIVtransplant.com. Accessed August 2010

95   **O'Grady J**, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). *HIV Med* 2005; **6** Suppl 2: 149-153

96   **Roland ME**, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, Freise CE, Benet LZ, Ascher NL, Roberts JP, Murphy B, Keller MJ, Olthoff KM, Blumberg EA, Brayman KL, Bartlett ST, Davis CE, McCune JM, Bredt BM, Stablein DM, Stock PG. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. *Am J Transplant* 2008; **8**: 355-365

97   **Testillano M**, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. *Transplant Proc* 2009; **41**: 1041-1043

98   **Hughes CB**, Dickson RC, Krishna M, Willingham DL, Satyanarayana R, Harnois DM, Keaveny AP, Rosser B, Aranda-Michel J, Kramer DJ, Hellinger W, Mendez J. HCV recurrence in HIV-infected patients after liver transplant. *J Int Assoc Physicians AIDS Care (Chic Ill)* 2010; **9**: 87-89

99   **Di Benedetto F**, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. *Transplantation* 2010; **89**: 733-738